- Home
- Publications
- Publication Search
- Publication Details
Title
Myeloma Bone Disease: A Comprehensive Review
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 12, Pages 6208
Publisher
MDPI AG
Online
2021-06-09
DOI
10.3390/ijms22126208
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma
- (2020) Stefania Raimondo et al. Cancers
- The Non-Coding RNA Landscape of Plasma Cell Dyscrasias
- (2020) Eugenio Morelli et al. Cancers
- Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis
- (2019) Stefania Raimondo et al. Journal of Hematology & Oncology
- Exosomal circRNAs: biogenesis, effect and application in human diseases
- (2019) Yangxia Wang et al. Molecular Cancer
- Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2018) Kenneth Anderson et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
- (2018) Noopur Raje et al. LANCET ONCOLOGY
- Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
- (2018) Philippe Moreau et al. LANCET ONCOLOGY
- Exosome-mediated transfer of lncRUNX2-AS1 from multiple myeloma cells to MSCs contributes to osteogenesis
- (2018) Bingzong Li et al. ONCOGENE
- Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases
- (2017) Andrew L. Himelstein et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Emerging treatment approaches for myeloma-related bone disease
- (2017) Maria Gavriatopoulou et al. Expert Review of Hematology
- Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma
- (2016) Ailing Lu et al. AMERICAN JOURNAL OF PATHOLOGY
- CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma
- (2016) James R. Berenson et al. BLOOD
- Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma
- (2016) J. Delgado-Calle et al. CANCER RESEARCH
- Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation
- (2016) Nicola Amodio et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- CYR61/CCN1 stimulates proliferation and differentiation of osteoblasts in vitro and contributes to bone remodelling in vivo in myeloma bone disease
- (2016) Hui Liu et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Current Controversies in the Management of Myeloma Bone Disease
- (2016) Rebecca Silbermann et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
- (2015) J. J. Shah et al. BLOOD
- Myeloma cell-derived Runx2 promotes myeloma progression in bone
- (2015) T. N. Trotter et al. BLOOD
- Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B
- (2015) Oddrun Elise Olsen et al. Cell Communication and Signaling
- Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study
- (2015) N. Raje et al. CLINICAL CANCER RESEARCH
- Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
- (2015) J. G. Berdeja et al. HAEMATOLOGICA
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation
- (2015) Lavinia Raimondi et al. Oncotarget
- Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
- (2015) J. G. Berdeja et al. HAEMATOLOGICA
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
- (2015) Neha Korde et al. JAMA Oncology
- Bortezomib enhances the osteogenic differentiation capacity of human mesenchymal stromal cells derived from bone marrow and placental tissues
- (2014) Tanwarat Sanvoranart et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
- (2014) S. Bringhen et al. BLOOD
- A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
- (2014) P. G. Richardson et al. BLOOD
- Sotatercept in patients with osteolytic lesions of multiple myeloma
- (2014) Kudrat M. Abdulkadyrov et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro
- (2014) Arnold Bolomsky et al. EXPERIMENTAL HEMATOLOGY
- Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro
- (2014) Yali Li et al. LEUKEMIA RESEARCH
- Osteoblastic Wnts differentially regulate bone remodeling and the maintenance of bone marrow mesenchymal stem cells
- (2013) Yong Wan et al. BONE
- Repetitively dosed docetaxel and153samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer
- (2013) Karen A. Autio et al. CANCER
- Cellular Mechanisms of Multiple Myeloma Bone Disease
- (2013) Angela Oranger et al. Clinical & Developmental Immunology
- New Strategies in the Treatment of Multiple Myeloma
- (2013) N. C. Munshi et al. CLINICAL CANCER RESEARCH
- Ibrutinib (PCI-32765) in Chronic Lymphocytic Leukemia
- (2013) Nitin Jain et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin
- (2013) Joachim Albers et al. JOURNAL OF CELL BIOLOGY
- International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease
- (2013) Evangelos Terpos et al. JOURNAL OF CLINICAL ONCOLOGY
- Palliative surgery in patients with unresectable colorectal liver metastases: a propensity score matching analysis
- (2013) Yong Sik Yoon et al. JOURNAL OF SURGICAL ONCOLOGY
- VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT
- (2013) E Terpos et al. LEUKEMIA
- Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
- (2013) Jan A. Burger et al. LEUKEMIA & LYMPHOMA
- Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis
- (2013) Munevver Cinar et al. LEUKEMIA RESEARCH
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Down-Regulation of Canonical and Up-Regulation of Non-Canonical Wnt Signalling in the Carcinogenic Process of Squamous Cell Lung Carcinoma
- (2013) Domokos Bartis et al. PLoS One
- Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma
- (2013) Bo Hu et al. PLoS One
- Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy
- (2012) E. Terpos et al. ANNALS OF ONCOLOGY
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
- (2012) S. Kumar et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- Developmental Stage and Time Dictate the Fate of Wnt/β-Catenin-Responsive Stem Cells in the Mammary Gland
- (2012) Renée van Amerongen et al. Cell Stem Cell
- The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
- (2012) M A Hurchla et al. LEUKEMIA
- Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation
- (2012) N Giuliani et al. LEUKEMIA
- Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
- (2012) Noopur Raje et al. Clinical Interventions in Aging
- Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease
- (2011) S. D'Souza et al. BLOOD
- Guidelines for the diagnosis and management of multiple myeloma 2011
- (2011) Jennifer M. Bird et al. BRITISH JOURNAL OF HAEMATOLOGY
- Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma
- (2011) Noopur Raje et al. CLINICAL CANCER RESEARCH
- Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients
- (2011) Maurizio Zangari et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma
- (2011) Michel Delforge et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
- (2011) Gareth J Morgan et al. LANCET ONCOLOGY
- A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
- (2011) S Vallet et al. LEUKEMIA
- Suppression of bone formation by osteoclastic expression of semaphorin 4D
- (2011) Takako Negishi-Koga et al. NATURE MEDICINE
- Percutaneous vertebroplasty to treat painful myelomatous vertebral deposits—long-term efficacy outcomes
- (2010) Paula Garland et al. ANNALS OF HEMATOLOGY
- The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3
- (2010) Giacomina Brunetti et al. Annals of the New York Academy of Sciences
- Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
- (2010) J.-L. Harousseau et al. BLOOD
- A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma
- (2010) K. Noonan et al. BLOOD
- Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma
- (2010) R. H. Prabhala et al. BLOOD
- RANKL and OPG activity is regulated by injury size in networks of osteocyte-like cells
- (2010) Lauren E. Mulcahy et al. BONE
- A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients
- (2010) M. Zangari et al. HAEMATOLOGICA
- The amazing osteocyte
- (2010) Lynda F Bonewald JOURNAL OF BONE AND MINERAL RESEARCH
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
- (2010) Gareth J Morgan et al. LANCET
- Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial
- (2010) Peter Gimsing et al. LANCET ONCOLOGY
- Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease
- (2010) E Terpos et al. LEUKEMIA
- TGF-β Inhibition Restores Terminal Osteoblast Differentiation to Suppress Myeloma Growth
- (2010) Kyoko Takeuchi et al. PLoS One
- Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
- (2010) S. Vallet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma
- (2009) Ravi Vij et al. AMERICAN JOURNAL OF HEMATOLOGY
- Bortezomib induces osteoblast differentiation via Wnt-independent activation of -catenin/TCF signaling
- (2009) Y.-W. Qiang et al. BLOOD
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
- (2009) M. Fulciniti et al. BLOOD
- Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells
- (2009) Thomas L. Andersen et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma
- (2009) Sarah Deleu et al. CANCER RESEARCH
- Dickkopf-1: a suitable target for the management of myeloma bone disease
- (2009) Maria Gavriatopoulou et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study
- (2009) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients
- (2009) S Colucci et al. LEUKEMIA
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
- (2009) H Quach et al. LEUKEMIA
- The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
- (2008) Angela Pennisi et al. AMERICAN JOURNAL OF HEMATOLOGY
- A Physical Mechanism for Coupling Bone Resorption and Formation in Adult Human Bone
- (2008) Thomas Levin Andersen et al. AMERICAN JOURNAL OF PATHOLOGY
- Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma
- (2008) Y.-W. Qiang et al. BLOOD
- The pathogenesis of the bone disease of multiple myeloma
- (2008) Claire M. Edwards et al. BONE
- Tyrosine Kinases Btk and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals
- (2008) Masahiro Shinohara et al. CELL
- Negative Regulation of the Osteoblast Function in Multiple Myeloma through the Repressor Gene E4BP4 Activated by Malignant Plasma Cells
- (2008) F. Silvestris et al. CLINICAL CANCER RESEARCH
- Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma
- (2008) Martin Kaiser et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- 153Sm: its use in multiple myeloma and report of a clinical experience
- (2008) Elisabetta Abruzzese et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Novel targets for myeloma bone disease
- (2008) G David Roodman EXPERT OPINION ON THERAPEUTIC TARGETS
- Radiotherapy for Extramedullary Plasmacytoma of the Head and Neck
- (2008) Kimberly M. Creach et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Building bone to reverse osteoporosis and repair fractures
- (2008) Sundeep Khosla et al. JOURNAL OF CLINICAL INVESTIGATION
- The cell biology of bone metabolism
- (2008) H K Datta et al. JOURNAL OF CLINICAL PATHOLOGY
- Bone marrow microenvironment and the identification of new targets for myeloma therapy
- (2008) K Podar et al. LEUKEMIA
- Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6
- (2008) Huang Hongming et al. LEUKEMIA RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started